

## Executive Summary

### Targeting Unmet Needs in Recurrent Aphthous Stomatitis (RAS)

#### Company Overview

Mucocort AB, founded in 2016, is a Swedish MedTech innovator based at the Umeå Biotech Incubator, a leading center for life science research. The company focuses on developing next-generation treatments for Recurrent Aphthous Stomatitis (RAS), a painful, highly prevalent and underserved condition affecting the oral mucosa. Mucocort is currently in a pre-commercial phase, operating as a virtual organization supported by its founders, a senior network of experts across medical device development, manufacturing, clinical trials, regulatory affairs, and IP protection.

#### M045A: Transformative Approach to RAS Management

Mucocort's flagship product, internal project name M045A, is a first-in-class, biodegradable, mucoadhesive patch engineered for direct application to oral ulcers. Classified as a Class IIa medical device, the patch delivers immediate pain relief, symptom reduction, and accelerated mucosal healing through a dual mechanism: Hygroscopic effect (absorbing wound exudate) and Non-pharmacological antimicrobial and anti-inflammatory action (suppressing cytokines IL-2 and TNF- $\alpha$ ). The patch forms a biocompatible gel barrier that naturally dissolves within 3–4 hours, offering a drug-free, steroid-free, and patient-friendly treatment.

#### Clinical and Regulatory Progress

Mucocort operates under ISO 13485 standards and has obtained regulatory approval in Sweden to initiate clinical trials according to ISO 14155, ISO 10993 and ISO 13485. Ongoing studies are assessing safety and effectiveness, supporting CE marking and future commercialization strategies.

#### Intellectual Property and Strategic Partnerships

Mucocort has a strong patent strategy and a long-lasting ip protection. Patents have been granted in Europe, China, Australia, and Japan with protection extending until 2040. Manufacturing has been secured through a strategic agreement with Aurena Laboratories, a leading CDMO in Sweden.

#### Tapping Into a USD 2.65 Billion Market with no Approved Therapies

RAS affects approximately 20% of the global population annually. The global mouth ulcer treatment market is projected to grow from USD 2.04 billion in 2023 to USD 2.65 billion by 2030. No approved prescription therapies exist for RAS, highlighting a significant unmet need.

#### Line extension Opportunities

With their modular and scalable platform, Mucocort can innovate into mucosal drug delivery, dermatology, pediatrics, geriatrics, and cosmetics. The company follows a streamlined '4R' innovation strategy: Re-purposing, Re-formulation, Re-positioning, and Re-patenting.

## Investment opportunity

The shareholders of Mucocort do not intend to establish a standalone commercial infrastructure to bring MO45A to the market. Instead, they are actively seeking a full acquisition by a partner with existing marketing and distribution capacity.

Mucocort offers a unique opportunity to acquire a very competitive, clinically validated, patent-protected MedTech technology with strong unmet market need, high-margin, scalable manufacturing and a clear regulatory pathway—positioning Mucocort as a highly potential addition to any medical device or consumer health portfolio.

- The shareholders of Mucocort have engaged Experia Corporate Finance Advisors as its exclusive financial advisors to find a new owner for the Company.
- Please contact the individuals at Experia Corporate Advisors listed below if you would like to proceed with further analysis and receive more information on the Company and the process.
- An Investment Memorandum is available upon execution of a confidentiality agreement.
- In no event should Mucocort, any of its affiliates, consultants, other advisors, or suppliers be contacted directly or indirectly to discuss this process.

### Experia Corporate Finance Advisors

Visitors: Biblioteksgatan 29  
SE-114 35 Stockholm, Sweden

Administration: Runda Vägen 13  
SE-167 51 Stockholm, Sweden

Håkan Persson  
Managing Partner  
+46 707 900 111

Daniel Gurmu  
Senior Advisor  
+46 739 46 25 53

[hakan.persson@experia.se](mailto:hakan.persson@experia.se)

[daniel.gurmu@experia.se](mailto:daniel.gurmu@experia.se)